Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

Matthew K. Hensley, William G. Bain, Jana Jacobs, Sham Nambulli, Urvi Parikh, Anthony Cillo, Brittany Staines, Amy Heaps, Michele D. Sobolewski, Linda J. Rennick, Bernard J.C. MacAtangay, Cynthia Klamar-Blain, Georgios D. Kitsios, Barbara Methé, Ashwin Somasundaram, Tullia C. Bruno, Carly Cardello, Feng Shan, Creg Workman, Prabir RayAnuradha Ray, Janet Lee, Rahil Sethi, William E. Schwarzmann, Mark S. Ladinsky, Pamela J. Bjorkman, Dario A. Vignali, W. Paul Duprex, Mounzer E. Agha, John W. Mellors, Kevin D. McCormick, Alison Morris, Ghady Haidar

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Abstract

A chimeric antigen receptor-modified T-cell therapy recipient developed severe coronavirus disease 2019, intractable RNAemia, and viral replication lasting >2 months. Premortem endotracheal aspirate contained >2 × 1010 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA copies/mL and infectious virus. Deep sequencing revealed multiple sequence variants consistent with intrahost virus evolution. SARS-CoV-2 humoral and cell-mediated immunity were minimal. Prolonged transmission from immunosuppressed patients is possible.

Original languageEnglish
Pages (from-to)E815-E821
JournalClinical Infectious Diseases
Volume73
Issue number3
DOIs
StatePublished - Aug 1 2021

Keywords

  • COVID-19
  • SARS-CoV-2 RNAemia
  • SARS-CoV-2 immune responses
  • SARS-CoV-2 infectivity
  • SARS-CoV-2 intrahost variation
  • severe acute respiratory syndrome coronavirus 2

Fingerprint

Dive into the research topics of 'Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study'. Together they form a unique fingerprint.

Cite this